Company profile

Pierre Fabre Medicament

Privately held: no public share price (Pierre Fabre Group is privately held; 86% owned by the Fondation Pierre Fabre, ~9.5% employee-owned; no traded equity. Parent: Fondation Pierre Fabre (86%). [resolved 2026-08-05 by resolve-null-is-public; source: https://www.pierre-fabre.com/en/annual-report-2024/unique-shareholding-structure]) · France

Assets

(4 total)

4Total Assets

0Approved

0Phase 3 / Filed

4Phase 1–2 / Early

1Diseases

Showing 4 of 4 assets

		Target & Modality
STX-241	Phase 2	EGFRSmall molecule	Non-Small Cell Lung Cancer
STX-721	Phase 2	EGFR/HER2Small molecule	Non-Small Cell Lung Cancer
VERT-002	Phase 2	METSmall molecule	Non-Small Cell Lung Cancer
KIN-2787	Phase 1	RAFSmall molecule	Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.